Business News

NICE Recommends Use of Pfizer’s Inlyta in Kidney Cancer and Rejects Dendreon’s Provenge for Prostate Cancer

The National Institute for Health and Care Excellence (NICE) issued two final guidelines, recommending Pfizer’s Inlyta (axitinib) in kidney cancer, but rejecting Dendreon’s Provenge (sipuleucel-T) in prostate cancer. In guidance issued to the NHS, the drug pricing watchdog recommended Inlyta as a second-line option for treating adults with advanced renal …

Read More »

Four New Centers Join World’s Largest Precision Cancer Research Network

The Oncology Research Information Exchange Network (ORIEN), founded by Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCC-James), announced that it has expanded with the addition of four nationally recognized cancer centers. ORIEN, a research …

Read More »

AstraZeneca Partners With Orca for Development of Oral Autoimmune Drugs

AstraZeneca is collaborating with UK-based Orca Pharmaceuticals to develop new drugs for a wide range of autoimmune diseases. The companies announced a three year collaboration to develop inhibitors of retinoic acid-related orphan nuclear receptor gamma (RORγ), which is believed to have potential against a wide range of autoimmune diseases for …

Read More »

Specialty Pharma Journal (SPJ) and Specialty Pharma Education Center (SPEC) Partner for Business-Based Educational Programs in Specialty Pharmacy

Tampa, FL, February 24, 2015 — Specialty Pharma Journal (SPJ) announced today that it has partnered with the Specialty Pharma Education Center (SPEC) to bring business-based educational programs to the specialty pharmacy industry. SPJ and SPEC are developing programs dedicated to education in biosimilars, 340B contracting, co-pay and coupon adjudication guidelines in …

Read More »

Merck Enters Drug Development Deal with NGM Biopharmaceuticals

Merck has signed a multi-year collaboration agreement with privately-held NGM Biopharmaceuticals to develop novel biologic therapies in a wide range of therapeutic areas. NGM said that it has entered a five-year collaboration to research, develop and commercialize drugs that treat diabetes, obesity and nonalcoholic steatohepatitis (NASH). Merck will pay NGM …

Read More »

Foundation Medicine and H3 Biomedicine Partner for Precision Medicine in Cancer

Today, Foundation Medicine, Inc. and H3 Biomedicine Inc. announced that they will collaborate to develop precision therapies for cancer. The companies said that they have entered a multi-year collaboration for the discovery and development of precision medicines in oncology, utilizing Foundation Medicine’s comprehensive genomic knowledgebase of more than 35,000 genomic …

Read More »

Genmab Enters DuoBody Technology Agreement with BioNovion in Immuno-Oncology

Genmab A/S and BioNovion struck a deal to evaluate several DuoBody product candidates targeting immune checkpoints. The companies announced that they have entered into a co-development and commercialization agreement to evaluate the product candidates. Genmab and BioNovion will contribute panels of antibodies for the creation of bispecific antibody products using …

Read More »